CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Trial of Maintenance Cemiplimab-rwlc After Concurrent Chemoradiotherapy (CRT) in Intermediate and High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04831450
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-28T10:38:33.189880+00:00
Published At: 2022-08-04T00:00:00+00:00
Record Updated At: 2022-08-04
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Head and Neck Squamous Cell Carcinoma", "HNSCC", "Squamous Cell Carcinoma of the Larynx", "Squamous Cell Carcinoma of the Oral Cavity", "Squamous Cell Carcinoma of Hypopharynx"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2022-08-04"
protocolSection.identificationModule.nctId: "NCT04831450"
protocolSection.identificationModule.officialTitle: "Phase II Trial of Maintenance Cemiplimab-rwlc After Concurrent Chemoradiotherapy (CRT) in Intermediate and High-Risk Head and Neck Squamous Cell Carcinoma (HNSCC)"
protocolSection.statusModule.overallStatus: "WITHDRAWN"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.